Pediatrics

Your Article Summary

See Latest Articles

Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: A therapeutic advances in Childhood Leukemia Consortium Study
Journal of Clinical Oncology, 10/22/09

Ko RH et al. – This study generally confirms a 40% CR rate for second and subsequent relapse, but our remission rate for early first relapse seems better than that reported in the literature (83% v approximately 70%). Our data may allow useful modeling of an expected remission rate for any population of patients who experience relapse.

• Retrospective cohort review of patients with relapsed and refractory ALL previously treated at TACL institutions between years of 1995 and 2004
• Data regarding initial and relapsed disease characteristics, disease response, and survival collected and compared with those of published reports

• Complete remission (CR) rates (mean ± SE) were 83% ± 4% for early first marrow relapse, 93% ± 3% for late first marrow relapse, 44% ± 5% for second marrow relapse, and 27% ± 6% for third marrow relapse
• Five-year DFS rates in CR2 and CR3 were 27% ± 4% and 15% ± 7% respectively

Today in Pediatric Heme/Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Pegfilgrastim in children with severe congenital neutropenia
Pediatric Blood & Cancer, 11/20/09

Embryonal carcinoma in a cryptorchid testis of a 3-year old
Pediatric Surgery International, 11/20/09

Symphysiotomy: a valuable approach in children with prostate rhabdomyosarcoma
Pediatric Surgery International, 11/19/09

 See all of Pediatric Heme/Oncology